Comparative analysis of PIK3CA mutation detection methods in the first-in-human phase 1/1b study of inavolisib.
Hilz S, Accordino M, Bedard P, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Oliveira M, Saura Manich C, Schmid P, Aimi J, Royer-Joo S, Schutzman J, Hutchinson K. Comparative analysis of PIK3CA mutation detection methods in the first-in-human phase 1/1b study of inavolisib. Journal Of Clinical Oncology 2025, 43: e13058-e13058. DOI: 10.1200/jco.2025.43.16_suppl.e13058.Peer-Reviewed Original ResearchMetastatic breast cancerHER2- metastatic breast cancerCtDNA testingNGS assaysTumor tissuesDetection concordanceTesting of tumor tissueFoundationOne Liquid CDxPIK3CA mutation testingFresh tumor tissueTissue-based testingBlood-based testOncogenic amino acid substitutionsBlood-based assayCatalytic subunit of PI3KSubunit of PI3KFoundation MedicineMutation detection methodsPIK3CA-mutationsTherapy regimenCtDNA sheddingAlpha catalytic subunitNG-TestReflex testAmino acid substitutions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply